Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Inclusion Criteria

• •Subject meets any of the following criteria and with sUA ≤10.0 mg/dL:
• •1. sUA level of \>7.0 mg/dL at 7 days prior to baseline with gout;
• •2. sUA level of ≥8.0 mg/dL at 7 days prior to baseline without gout but with complications (hypertension, ischemic heart disease, diabetes, metabolic syndrome);
• •3. sUA level of ≥9.0 mg/dL at 7 days prior to baseline without gout and complications.